2019年美国血液学会镰状细胞病指南:方法学、挑战与创新
ASH组建5个多学科指南小组,针对镰状细胞病的疼痛、脑血管并发症、肺与肾脏并发症、输血及造血干细胞移植5个管理领域制定临床实践推荐。Mayo Clinic循证实践中心基于预设问题开展系统评价,指南采用GRADE方法及证据到决策框架,并描述了患者培训课程、应对阿片类药物危机及处理间接与非比较证据等创新方案。
要点
- ASH针对镰状细胞病5个重要管理领域制定临床实践推荐。
- 指南小组由患者代表、内容专家和方法学家多学科组成。
- 采用GRADE方法评估证据确定性并应用证据到决策框架。
核心结论
- ASH通过5个多学科小组为镰状细胞病5个管理领域制定临床实践推荐,并采用GRADE方法及证据到决策框架。
研究设计与样本
- ASH召集5个指南小组,针对镰状细胞病的疼痛、脑血管并发症、肺与肾脏并发症、输血及造血干细胞移植5个管理领域制定推荐。
- 小组为多学科构成,包括患者代表、内容专家和方法学家;Mayo Clinic循证实践中心基于预设问题开展系统评价。
主要发现
- 指南制定过程包括使用GRADE方法对证据确定性进行分级,并应用GRADE证据到决策框架。
- 指南小组面临若干独特挑战,并采用了特定创新与解决方案,包括培训患者参与指南开发的课程、应对阿片类药物危机以及处理间接与非比较证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted systematic reviews based on a priori selected questions. In this exposition, we describe the process used by ASH, including the GRADE approach (Grades of Recommendations, Assessment, Development and Evaluation) for rating certainty of the evidence and the GRADE Evidence to Decision Framework. We also describe several unique challenges faced by the guideline panels and the specific innovations and solutions used to address them, including a curriculum to train patients to engage in guideline development, dealing with the opioid crisis, and working with indirect and noncomparative evidence.
引用
- Murad MH, Liem RI, Lang ES, et al. 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Adv. 2019. PMID: 31794603. doi:10.1182/bloodadvances.2019000931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。